In 2015 we began collaboration with the Duke Center for Applied Genomics and Precision Medicine and with the Department of Surgery’s Surgical Critical Care Initiative (Sc2i) to develop a line of translational research. This work also culminated in some key partnerships with senior discovery scientists.
We continue this mechanistic research work in multiple labs and collaborations across Duke University.
Dr. Sam Francis studies thrombosis in the Arepally Lab and is able to extend her lab's work to the acute care setting.
Dr. John Eppensteiner studies sterile inflammation in acute conditions such as traumatic injury in conjunction with the Sc2i and Duke COVID repository efforts.
Dr. Alex Limkakeng received multiple internal and external grants to study “-omics” in various forms in patients at risk for acute coronary syndrome.
In 2017, Bruce Derrick, MD obtained a pivotal grant from the Department of the Navy to study a ketogenic diet to reduce the effects of oxygen toxicity in conjunction with the hyperbarics group at Duke and he continues to study pulmonary physiology in the hyperbarics chamber.
Lastly, Charles Gerardo, MD, has extended his clinical research into translational study of immunologic markers following snakebite envenomation and the effects of antivenom. This work has led to a better understanding immune response to snakebite envenomation, which is a leading cause of morbidity and mortality worldwide.
Moving from the study of molecules to health systems, our Division of Translational Health Sciences — led by Dr. Joao Vissoci — explores innovative ways to bring our current knowledge to bear at the bedside. They use techniques including geographic information systems, advanced data science, and qualitative methods to advance the delivery of health care on national levels.
We intend to continue to invest in these and other areas of discovery science in the coming years, producing robust collaborations and synergistically increasing opportunities for the Duke community.
